Evidence map›Paper›PMID 29378659›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2018

Diagnostic performance of

Masatoshi Hotta, Ryogo Minamimoto, Hideaki Yano, Yoshimasa Gohda, Yasutaka Shuno

Abstract readComparative StudyEvaluation Study
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Moving the goalposts while scoring-the dilemma posed by new PET technologies.European journal of nuclear medicine and molecular imaging · 2021
    Article
  7. New PET technologies - embracing progress and pushing the limits.European journal of nuclear medicine and molecular imaging · 2021
    Article
  8. Improving staging of rectal cancer in the pelvis: the role of PET/MRI.European journal of nuclear medicine and molecular imaging · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Masatoshi HottaDivision of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, 1-21-1, Shinjuku-ku, Toyama, Tokyo, 162-8655, Japan. masatoshihotta@yahoo.co.jp.ORCID http://orcid.org/0000-0001-6790-8804
Ryogo MinamimotoDivision of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, 1-21-1, Shinjuku-ku, Toyama, Tokyo, 162-8655, Japan.
Hideaki YanoDepartment of Surgery, National Center for Global Health and Medicine, 1-21-1, Shinjuku-ku, Toyama, Tokyo, 162-8655, Japan.
Yoshimasa GohdaDepartment of Surgery, National Center for Global Health and Medicine, 1-21-1, Shinjuku-ku, Toyama, Tokyo, 162-8655, Japan.
Yasutaka ShunoDepartment of Surgery, National Center for Global Health and Medicine, 1-21-1, Shinjuku-ku, Toyama, Tokyo, 162-8655, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccurate staging is crucial for treatment selection and prognosis prediction in patients with rectal cancer. Point spread function (PSF) reconstruction can improve spatial resolution and signal-to-noise ratio of PET imaging. The aim of this study was to evaluate the effectiveness of

methodsA total of 59 patients with rectal cancer underwent preoperative

resultsFor N staging, PSF-PET/CT provided higher sensitivity (78.6%) than conventional PET/CT (64.3%), and pelvic MRI (57.1%), and all techniques showed high specificity (PSF-PET: 95.4%, conventional PET: 96.7%, pelvic MRI: 93.5%). SUVmax and L/B ratio were significantly higher in PSF-PET/CT than conventional-PET/CT (p < 0.001). The accuracy for T staging in PSF-PET/CT (69.4%) was not significantly different to conventional PET/CT (73.5%) and pelvic MRI (73.5%). MTVs of PSF and conventional PET showed a significant difference among T stages (p < 0.001), with higher values in advanced stages. In M staging, both PSF and conventional PET/CT diagnosed all distant metastases correctly.

conclusionsPSF-PET/CT produced images with higher lesion-to-background contrast than conventional PET/CT, which allowed improved detection of lymph node metastasis without compromising specificity, and showed comparable diagnostic value to MRI in local staging. PSF-PET/CT is likely to have a great value for initial staging in rectal cancer.

Indexed as

AgedFemaleFluorodeoxyglucose F18HumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingPelvisPositron Emission Tomography Computed TomographyRadiopharmaceuticalsRectal NeoplasmsSensitivity and SpecificityFluorodeoxyglucose F18Radiopharmaceuticals18F-FDG pet/ctPelvic MRIPoint spread function (PSF)Rectal cancerStaging

Identifiers

PMID29378659
PMCPMC5789619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.